Search
Inula helenium root
go.drugbank.com/drugs/DB14350ApprovedInula helenium root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Idarubicin
go.drugbank.com/drugs/DB01177ApprovedInvestigationalAn orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Chromanol
go.drugbank.com/drugs/DB13111InvestigationalChromanol has been used in trials studying the treatment of Prostate Cancer.
Categories: Compounds used in a research, industrial, or household settingExisulind
go.drugbank.com/drugs/DB06246InvestigationalCategories: Compounds used in a research, industrial, or household settingCiluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
Indium In-111 oxyquinoline
go.drugbank.com/drugs/DB09473ApprovedIt is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. … It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections
Synonyms: In-111 oxyquinoline, Indium In-111 oxineProducts: Indium In 111 Oxyquinoline, Indium in 111 OxyquinolineNiflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Diacerein
go.drugbank.com/drugs/DB11994ApprovedInvestigationalWithdrawnIt is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.